Temporary Erythropoiesis Hypoactivity Following Hypoxia‐Inducible‐Factor‐Prolyl‐Hydroxylase‐Inhibitor Discontinuation

Recently, hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) have been introduced as a therapeutic option for anemia, a common complication of chronic kidney disease. Although HIF-PHIs demonstrate efficacy in managing anemia, their administration may lead to dependence on upregulated hypoxia-inducible factors. Here, we report two maintenance hemodialysis cases that experienced temporary erythropoiesis hypoactivity following HIF-PHI discontinuation.